πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated β€” grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≀24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β€” use filters for patent-cliff planning.

Page 117 of 173

  1. US 8192720

    Compositions and methods for detection, prevention, and treatment of anthrax and other infectious diseases

    Expires Mon May 31 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8192991

    Methods of eliciting or boosting a cellular immune response

    Expires Mon May 31 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8193330

    Polynucleotides comprising Neurogenin3 promoter and bHLH encoding domains

    Expires Mon May 31 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8193312

    Bone morphogenic protein binding peptide

    Expires Mon May 31 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8193225

    Isoxazole amides, derivatives and methods of chemical induction of neurogenesis

    Expires Mon May 31 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8193152

    Treatment or prevention of hemorrhagic viral infections with immunomodulator compounds

    Expires Mon May 31 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8193145

    Laminins, derivatives, and compositions including same and methods for their therapeutic use

    Expires Mon May 31 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8193309

    Compositions and methods for preventing or treating cancer

    Expires Mon May 31 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8188072

    Benzodiazepinone compounds useful in the treatment of skin conditions

    Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8188289

    Conformationally restricted urea inhibitors of soluble epoxide hydrolase

    Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8188221

    Peptide homing to brain tumors

    Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8188219

    Bone morphogenic protein binding peptide

    Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8188049

    Peptides having activities of epidermal growth factor and its uses

    Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8187708

    Microphasic micro-components and methods for controlling morphology via electrified jetting

    Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8187591

    Methods of treating coagulopathy

    Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8182807

    Method for inhibiting reperfusion injury in the brain

    Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8185186

    Systems and methods for tissue imaging

    Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8183344

    Inactivation resistant factor VIII

    Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8183282

    Therapeutic uses of urolithins

    Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8183274

    Treatment of hyperproliferative disorders with diarylhydantoin compounds

    Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8183012

    Methods and composition for the production of orthogonal tRNA-aminoacyltRNA synthetase pairs

    Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8178298

    Patched polypeptides and uses related thereto

    Expires Mon May 10 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8178076

    Diagnosis and assessment of skeletal related disease using calcium 41

    Expires Mon May 10 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8173364

    Methods and composition for the production of orthogonal tRNA-aminoacyl tRNA synthetase pairs

    Expires Mon May 03 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8173602

    Detecting CYP24 expression level as a marker for predisposition to cancer

    Expires Mon May 03 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8173392

    In vivo incorporation of unnatural amino acids

    Expires Mon May 03 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8173115

    Particle compositions with a pre-selected cell internalization mode

    Expires Mon May 03 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8173424

    Internalizing ErbB2 antibodies

    Expires Mon May 03 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8168585

    Purification of peptides from colostrum

    Expires Mon Apr 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8168391

    Method for modulating insulin production

    Expires Mon Apr 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8168800

    AΞ²-binding small molecules

    Expires Mon Apr 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8168754

    Modified vitamin K-dependent polypeptides

    Expires Mon Apr 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8168626

    Benzodiazepine compositions for treating epidermal hyperplasia and related disorders

    Expires Mon Apr 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8168591

    Compositions and methods related to anti-FGF agents

    Expires Mon Apr 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8168423

    Device for detecting nitrosothiol content in solution

    Expires Mon Apr 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8168222

    Amphiphilic polymer-protein conjugates and methods of use thereof

    Expires Mon Apr 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8168200

    Vaccine against african horse sickness virus

    Expires Mon Apr 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8168415

    Axl fusion proteins as Axl tyrosine kinase inhibitors

    Expires Mon Apr 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8163805

    Small molecule antagonists of Bcl-2 family proteins

    Expires Mon Apr 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8163893

    Pseudotyped retroviral vectors and methods of use thereof

    Expires Mon Apr 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8163509

    Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors

    Expires Mon Apr 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8163881

    Immunoglobulin molecules with improved characteristics

    Expires Mon Apr 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8163548

    Recombinant bicistronic flaviviruses and methods of use thereof

    Expires Mon Apr 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8163281

    Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis

    Expires Mon Apr 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8163709

    TAK1-D mediated induction of cell death in human cancer cells by specific sequence short double-stranded RNAS

    Expires Mon Apr 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8163294

    Growth regulatable recombinant BCG compositions

    Expires Mon Apr 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8162918

    Gels with predetermined conductivity used in electroporation of tissue

    Expires Mon Apr 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8158596

    Materials and methods for FOXP3 tumor suppression

    Expires Mon Apr 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.